Russell Investments Group Ltd. Sells 21,365 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Russell Investments Group Ltd. reduced its position in Supernus Pharmaceuticals by 22.2% in the first quarter, now holding 75,030 shares valued at approximately $2.5 million.
• Insider trading activity included significant sales by Director Frederick M. Hudson and CEO Jack A. Khattar, with Khattar selling 140,000 shares for nearly $5.9 million.
• Several analysts have provided positive outlooks on Supernus Pharmaceuticals, with Zacks upgrading the stock from a "strong sell" to a "hold" and Cantor Fitzgerald increasing the price target to $46.00.

Russell Investments Group Ltd. cut its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 75,030 shares of the specialty pharmaceutical company's stock after selling 21,365 shares during the period. Russell Investments Group Ltd. owned approximately 0.13% of Supernus Pharmaceuticals worth $2,457,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vident Advisory LLC boosted its stake in Supernus Pharmaceuticals by 2.2% during the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company's stock valued at $520,000 after buying an additional 309 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Supernus Pharmaceuticals by 2.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,664 shares of the specialty pharmaceutical company's stock valued at $480,000 after buying an additional 350 shares during the last quarter. Raiffeisen Bank International AG bought a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $25,000. PNC Financial Services Group Inc. boosted its stake in Supernus Pharmaceuticals by 4.7% during the first quarter. PNC Financial Services Group Inc. now owns 16,097 shares of the specialty pharmaceutical company's stock valued at $527,000 after buying an additional 726 shares during the last quarter. Finally, Quantinno Capital Management LP boosted its stake in Supernus Pharmaceuticals by 11.5% during the fourth quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company's stock valued at $304,000 after buying an additional 864 shares during the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 14,000 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $44.51, for a total value of $623,140.00. Following the sale, the senior vice president directly owned 15,496 shares in the company, valued at approximately $689,726.96. This represents a 47.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Timothy C. Dec sold 11,780 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total value of $524,092.20. Following the completion of the sale, the chief financial officer owned 1,246 shares in the company, valued at approximately $55,434.54. The trade was a 90.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 179,606 shares of company stock valued at $7,617,005. Company insiders own 8.80% of the company's stock.

Wall Street Analysts Forecast Growth

SUPN has been the topic of a number of recent research reports. Piper Sandler upped their price objective on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research report on Friday. Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $43.00.

Supernus Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ SUPN traded down $0.25 during midday trading on Friday, hitting $45.12. The company's stock had a trading volume of 481,773 shares, compared to its average volume of 1,012,080. The business's 50 day moving average is $36.63 and its two-hundred day moving average is $33.94. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $45.60. The firm has a market cap of $2.53 billion, a P/E ratio of 39.23 and a beta of 0.74.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.